🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
GILD
NASDAQ
🇺🇸 US
Gilead Sciences, Inc.
Pharmaceuticals
24Score
DipBuster Score™
$174.48
+$7.01 (+4.19%)
Live price · Source: Yahoo
52-Week Position
$116.88
98% of range
$175.65
Beta
0.365
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.365
52W High$175.65
52W Low$116.88
DipBuster Brief
Key signals at a glance
Zone: Sell / Avoid
Bearish
Near 52-Week High — Asymmetric Risk
At 98% of its annual range the stock is close to its peak. New buyers face limited upside and meaningful downside if sentiment shifts.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position98% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.365
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Gilead Sciences, Inc. (GILD), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-11-02 | O'day Daniel Patrick | SELL | 2,000 |
| 2026-11-02 | O'day Daniel Patrick | SELL | 7,796 |
| 2026-11-02 | O'day Daniel Patrick | SELL | 1,904 |
| 2026-11-02 | O'day Daniel Patrick | SELL | 1,700 |
| 2026-11-02 | O'day Daniel Patrick | SELL | 1,600 |
| 2026-10-30 | O'day Daniel Patrick | SELL | 15,881 |
| 2026-10-30 | O'day Daniel Patrick | SELL | 15,881 |
| 2026-10-30 | O'day Daniel Patrick | BUY | 15,881 |
| 2026-10-15 | Mercier Johanna | SELL | 3,000 |
| 2026-10-15 | Dickinson Andrew D | SELL | 3,000 |
Valuation
P/E RatioN/A
Market CapN/A
Beta0.365
Dividend/yrNone
52W High$175.65
52W Low$116.88
52-Week Range
$116.88Now$175.65
98% through annual range
From 52W High−0.7%
From 52W Low+49.3%
📖 Plain English Summary
Gilead Sciences, Inc. is at 98% of its 52-week range. Beta 0.365 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for GILD
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — GILD
Heuristic · balance sheet, insider filings, price data, academic research
Gilead Sciences, Inc. — DipBuster Score 24/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Gilead Sciences, Inc. free
Add GILD to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Freetrade
Simple investing app. Free ISA. UK and US stocks. FCA regulated.
Free share when you fund your account
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
1/25
Momentum & Volume
18/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
0
/100 · NEUTRAL
dip depth
0/25
oversold rsi
0/25
mean reversion
0/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 24/100
📈
Strong recent momentum — price and volume trending in the right direction.
Company Profile
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializi…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
Daniel O'Day
Staff
17,000 employees
Website